{"id":7,"date":"2022-08-16T17:35:27","date_gmt":"2022-08-16T17:35:27","guid":{"rendered":"https:\/\/vimizimhcp-dev-001.azurewebsites.net\/en-us\/vimizim\/?page_id=7"},"modified":"2023-05-04T08:45:46","modified_gmt":"2023-05-04T08:45:46","slug":"home","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","title":{"rendered":"Home"},"content":{"rendered":"
\n
<\/div>\n\t
<\/div>\n \t
<\/div>\n\t
\n\t\t
\n\t\t\t
\n

VIMIZIM\u00ae<\/sup>
\n(elosulfase alfa)\n<\/h1>\n

The first and only enzyme replacement therapy for people with Morquio A syndrome1,2<\/sup><\/p>\n

Connect with BioMarin to receive news, information, and support.<\/p>\n

REGISTER FOR UPDATES<\/a><\/p>\n <\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n

\n\t
\n\t\t
\n\t\t
\n \n \n \n \n
\n
\n \"heterogenity\" <\/div>\n <\/figure>\n <\/div>\n \n
\n

VIMIZIM demonstrated early and sustained improvement in endurance in clinical trials1-3<\/sup><\/h2>\n

Significant impact on endurance as measured by the 6-minute walk test (6MWT) was seen as early as week 12 and sustained over 120 weeks.1-3<\/sup><\/p>\n

Review VIMIZIM efficacy data <\/a><\/p>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t
\n

Is Morquio A hiding in your practice?<\/h2>\n

Diverse presentations of Morquio A can complicate identification. When patients do not present with classic signs (eg, bone deformity, short stature, genu valgum), they may be challenging to identify.4<\/sup><\/p>\n

Learn more about the heterogeneity of Morquio A <\/a><\/p>\n <\/div>\n \n

\n \n \n \n \n
\n
\n \"\" <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t
\n

Recognize the signs and symptoms of Morquio A, a multisystemic genetic disorder1,5,6<\/sup><\/h2>\n

Because glycosaminoglycan (GAG) accumulation can lead to progressive organ damage across multiple systems, it is important to recognize the various symptoms of Morquio A.4,5<\/sup><\/p>\n

Explore Morquio A signs, symptoms, and complications<\/a><\/p>\n <\/div>\n \n

\n \n \n \n \n
\n
\n \"\" <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\n
\n
\n
\n
\n \"rare <\/div>\n <\/figure>\n <\/div>\n
\n

BioMarin RareConnections\u2122: Uncommon support for rare disease\n<\/h3>\n

BioMarin RareConnections\u2122 can help patients with Morquio A gain access to VIMIZIM.<\/p>\n

Learn more about BioMarin RareConnections\u2122<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t \t\t\t

References:\n<\/h4>\n\t\t\t\t\t\t
    \n
  1. VIMIZIM [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2019.\n<\/span><\/li>\n
  2. Hendriksz CJ, Parini R, AlSayed M, et al<\/em>. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab<\/em>. 2016;119(1-2):131-143.\n<\/span><\/li>\n
  3. Hendriksz CJ, Burton B, Fleming TR, et al<\/em>. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis<\/em>. 2014;37(6):979-990.\n<\/span><\/li>\n
  4. Akyol MU, Alden TD, Amartino H, et al<\/em>. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis<\/em>. 2019;14:137.\n<\/span><\/li>\n
  5. Tomatsu S, Monta\u00f1o AM, Oikawa H, et al<\/em>. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol<\/em>. 2011;12(6):931-945.\n<\/span><\/li>\n
  6. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis<\/em>. 1996;19(3):357-365.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-7","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nEnzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)<\/title>\n<meta name=\"description\" content=\"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)\" \/>\n<meta property=\"og:description\" content=\"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Vimizim HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T08:45:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\",\"name\":\"Enzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\"},\"datePublished\":\"2022-08-16T17:35:27+00:00\",\"dateModified\":\"2023-05-04T08:45:46+00:00\",\"description\":\"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\",\"name\":\"BioMarin Vimizim HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)","description":"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","og_locale":"en_US","og_type":"article","og_title":"Enzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)","og_description":"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","og_site_name":"BioMarin Vimizim HCP EN-US","article_modified_time":"2023-05-04T08:45:46+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","name":"Enzyme replacement therapy for Morquio A | VIMIZIM\u00ae (elosulfase alfa)","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website"},"datePublished":"2022-08-16T17:35:27+00:00","dateModified":"2023-05-04T08:45:46+00:00","description":"VIMIZIM\u00ae (elosulfase alfa) is the first and only enzyme replacement therapy (ERT) for people with Morquio A. View boxed warning, including risk of anaphylaxis.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/vimizim\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","name":"BioMarin Vimizim HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/7","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/comments?post=7"}],"version-history":[{"count":150,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/7\/revisions"}],"predecessor-version":[{"id":2884,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/7\/revisions\/2884"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/media?parent=7"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}